Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
Items 201–300 of 808
Lazarus, J. E., Wang, Y., Waldor, M. K., & Hooper, D. C. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-23 · Cited by 12
Salpadoru, T., Pinks, K. E., Lieberman, J. A., Cotton, K., Wozniak, K. L., Gerasimchuk, N., & Patrauchan, M. A. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04234-23 · Cited by 13
Panlilio, H., Lam, A. K., Heydarian, N., Haight, T., Wouters, C. L., Moen, E. L., & Rice, C. V. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00863 · Cited by 12
Wang, H., & Palasik, B. N. (2022) · Therapeutic Advances in Urology · doi:10.1177/17562872211065570 · Cited by 14
McCrink, K. A., DeRonde, K., Jiménez, A., Roselló, G., Natori, Y., Claeys, K. C., Martínez, O., Pascale, B. D., Pérez-Cardona, A., Abbo, L. M., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106811 · Cited by 12
Hareza, D. A., Cosgrove, S. E., Simner, P. J., Harris, A. D., Bergman, Y., Conzemius, R., Jacobs, E. B., Beisken, S., & Tamma, P. D. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad703 · Cited by 13
Self-citationFerliçolak, L., Altıntaş, N. D., & Yörük, F. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.11.004 · Cited by 11
Abi Manesh, S., George, M. M., Palanikumar, P., Nagaraj, V., Bhanuprasad, K., Krishnan, R., Nivetha, G., Lal, B., Triveni, K. R., Gautam, P., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01042-w · Cited by 11
“Given such limitations and pending further data, the IDSA guidelines suggest consideration of combination therapy consisting of two active agents with high-dose sulbactam as a core component [1].”
Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor
Lanier, C., Melton, T. C., & Covert, K. L. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241279904 · Cited by 11
“6 While new medications are being developed, these advances are not without controversy related to outcome objectives, non-serious infections, and lack of in vivo clinical data.”
Zohar, I., Maor, ., Shirin, N., & Yahav, D. (2024) · CMI Communications · doi:10.1016/j.cmicom.2024.105039 · Cited by 11
Farooq, A., Martens, M., Kroemer, N., Pfaffendorf, C., Decousser, J., Nordmann, P., & Wicha, S. G. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae459 · Cited by 11
Dong, L., Huang, Y., Zhang, S., Xu, B., Li, B., & Cao, Y. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s495240 · Cited by 12
“14 Molecular screening of antibiotic resistance genes is very important to investigate the resistance mechanism of P. aeruginosa .”
Treatment of Resistant Gram-negative bacilli in children
Cohen, R., Dortet, L., Caséris, M., Raymond, J., Lorrot, M., & Toubiana, J. (2023) · Infectious Diseases Now · doi:10.1016/j.idnow.2023.104794 · Cited by 11
Dequidt, T., Bastian, S., Nacher, M., Breurec, S., Carles, M., Thiéry, G., Camous, L., Tressières, B., Valette, M., & Pommier, J. (2023) · Critical Care · doi:10.1186/s13054-023-04712-2 · Cited by 11
Deschamps, M., Dauwalder, O., & Dortet, L. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad407 · Cited by 11
Black, C. A., Benavides, R., Bandy, S. M., Dallas, S. D., Gawrys, G. W., So, W., Moreira, A. G., Aguilar, S., Quidilla, K., Smelter, D. F., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13020185 · Cited by 11
Borzych–Dużałka, D., Same, R., Neu, A. M., Yap, H., Verrina, E. E., Bakkaloglu, S. A., Cano, F. J., Patel, H. P., Szczepańska, M., Obrycki, Ł., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.03.031 · Cited by 11
Słabisz, N., Leśnik, P., Janc, J., Fidut, M., Bartoszewicz, M., Dudek-Wicher, R. K., & Nawrot, U. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1331628 · Cited by 11
Rezzonico, L. F., Peracchi, F., Vecchi, M., Bassi, G., Merli, M., Bana, N. B., Travi, G., Crippa, F., & Puoti, M. (2024) · Antibiotics · doi:10.3390/antibiotics13040331 · Cited by 11
Walker, M. K., Diao, G., Warner, S., Babiker, A., Neupane, M., Strich, J. R., Yek, C., & Kadri, S. S. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00149-x · Cited by 11
Luo, T. L., Martin, M. J., Kovalchuk, V., Kondratiuk, V., Trapaidze, N., Metreveli, M., Hulseberg, C. E., Dao, H. D., Kwak, Y. I., Maybank, R. A., et al. (2024) · Eurosurveillance · doi:10.2807/1560-7917.es.2024.29.24.2400259 · Cited by 11
“Of particular concern is the high rate of resistance to carbapenem antibiotics (> 50% in 21 European countries in 2020-2022 [13]), that makes treatment difficult [14].”
BackgroundTickler, I. A., Kawa, D. E., Obradovich, A. E., Fang, F. C., Tenover, F. C., & Infections, T. H. A. (2023) · Antibiotics · doi:10.3390/antibiotics12091386 · Cited by 11
Maćešić, N., Dennis, A. S. M., Hawkey, J., Vezina, B., Wisniewski, J. A., Cottingham, H., Blakeway, L. V., Harshegyi, T., Pragastis, K., Badoordeen, G. Z., et al. (2024) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2024.8 · Cited by 10
A retrospective study of the efficacy and safety of levofloxacin in children with severe infection
Junqi, Z., Cai, J., Wang, J., Lu, J., Lü, G., Wang, Y., & Li, Z. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1381742 · Cited by 12
Liu, T., Xu, H.-R., Huang, T., Liu, G., Cao, H., Lin, Y., Li, Y., Li, Y., & Yao, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118365 · Cited by 10
Yang, S., Su, P., Lü, L., Liu, S., & Wang, Y. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101117 · Cited by 11
“For example, b -lactamases can degrade the b -lactam ring in b -lactam antibiotics to render them ineffective [24].”
Threat of multidrug resistant bacteria: The role of genomic solutions and a call to action
Mallik, S., Dash, S., Mishra, S., Mohanty, R. B., Sahoo, S., Patra, A., Sahoo, S., Mishra, R., & Mohanty, J. N. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102298 · Cited by 12
Yan, W., Liang, J., Liu, M., Hu, X., Zhang, H., Guo, J., & Li, L. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s530585 · Cited by 10
“29 However, high resistance to fluoroquinolones and cotrimox-azole has been found in our study, consistent with prior research.”
Duduveche, A.-E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052378 · Cited by 10
Current progress in antibacterial agents for carbapenem-resistant enterobacterales
Xu, W., Shang, L., Li, X., Yu, J., Shen, J., Li, Y., He, Q., Chen, L., Wang, D., Wei, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1796557 · Cited by 11
Abel, A. L. V., Childs‐Kean, L. M., Jensen, K. L., Mynatt, R. P., Ryan, K. L., & Rivera, C. G. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231191877 · Cited by 13
“They paged me what?”: A transplant infectious disease guide to donor calls
Gorsline, C. A., Tyler, R. S., Sigler, R., Wolfe, C. R., Harris, C. E., & Kumar, R. N. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14172 · Cited by 10
Almangour, T. A., Alali, H. A., Alkherb, Z., Alowais, S. A., Saleh, K. B., Almuhisen, S., Almohaizeie, A., Alsahli, R., Alruwaite, S., Alnashmi, F., et al. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2353704 · Cited by 10
Boscolo, A., Bruni, A., Giani, M., Garofalo, E., Sella, N., Pettenuzzo, T., Bombino, M., Palcani, M., Rezoagli, E., Pozzi, M., et al. (2024) · Critical Care · doi:10.1186/s13054-024-05068-x · Cited by 10
“The definitions of ventilator-associated pneumonia (VAP) or non-VAP, bloodstream infection (BSI)/catheter-related bloodstream infection (CR-BSI), urinary tract infection (UTI) etc. are provided in additional-Methods 115 , 20, 28–31.”
BackgroundMethodInfluentialLai, X., Yu, L., Huang, X., Gardner, W., Bamford, S. E., Pigram, P. J., Wang, S., Brun, A. P. L., Muir, B. W., Song, J., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403046 · Cited by 10
Jean, S., Liu, C., Huang, T., Lai, C.-C., Liu, I.-M., Hsieh, P.-C., & Hsueh, P. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2412637 · Cited by 11
Spottiswoode, N., Hao, S. L., Sanchez-Guerrero, E., Detweiler, A. M., Mekonen, H. E., Neff, N. F., Macmillan, H., Schwartz, B. S., Engel, J. N., DeRisi, J. L., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1241608 · Cited by 9
Antibiotic Resistance Trends Among Enterobacteriaceae in Saudi Arabia: A Systematic Review
Arafah, A. A. (2024) · Cureus · doi:10.7759/cureus.56614 · Cited by 12
“In recent years, novel β -lactam/ β -lactamase inhibitor combinations have been approved for the management of resistant organisms such as Enterobacteriaceae [6-8].”
BackgroundKhurana, M. P., Curran-Sebastian, J. L., Bhatt, S., & Knight, G. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-66193-9 · Cited by 9
Prolonged Beta-Lactam Infusions in Children: A Systematic Review and Meta-Analysis
Briand, A., Bernier, L., Pincivy, A., Roumeliotis, N., Autmizguine, J., Marsot, A., Métras, M., & Thibault, C. (2024) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2024.114220 · Cited by 10
“80,81 Twoelementsarecrucialtoconsiderwhenassessingantimi-crobialefficacy:thebacterialMICandthePK/PDtargetneeded toeradicatethebacteria.”
Lei, Z., Li, Z., Zhang, Y., Zeng, L., Wu, Y., Zhang, F., Yang, X., Liu, X., Liu, Q., Ma, Y., et al. (2024) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-024-00743-x · Cited by 9
Kim, S., Ji, S., Cho, D., Lee, A. K., Jeong, H. S., Kim, M., Kim, S. E., Park, K., Jung, S., Kim, U. J., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12122477 · Cited by 9
Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
Sajib, M. I., Monteforte, M., & Go, R. (2023) · Antibiotics · doi:10.3390/antibiotics12050936 · Cited by 10
Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
August, B., Matlob, A., & Kale-Pradhan, P. B. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231204566 · Cited by 9
“6,25 The findings from the landmark phase III clinical trial comparing SUL-DUR to colistin are promising.”
BackgroundAlabdali, Y. A. J., Azeez, D. A., Munahi, M. G., & Kuwait, Z. I. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01076-y · Cited by 9
Vatterrodt, D., Lee, J., Ho, D., Stevig, C., & Chow, S.-K. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00542-24 · Cited by 9
Kim, T. Y., Kang, M., Shim, H. J., Kang, O., Huh, H. J., & Lee, N. Y. (2024) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.25043 · Cited by 9
“Aminoglycosides are one of the most effective drugs used for CRE infections, particularly urinary tract infections [29], and addressing high VME rates for these drugs should be a focus in the next version of QMAC-dRAST.”
BackgroundLin, Y.-C., Yang, K., Peng, C., Chan, M.-C., Sheu, C., Feng, J., Wang, S., Huang, W.-H., Chen, C.-M., Chen, C., et al. (2024) · Infection · doi:10.1007/s15010-024-02343-5 · Cited by 9
Zilberberg, M. D., Nathanson, B. H., Redell, M. A., Sulham, K., & Shorr, A. F. (2025) · Antibiotics · doi:10.3390/antibiotics14010029 · Cited by 9
“Recent guidance from the Infectious Diseases Society of America underscores this fact by noting that their recommendations for the treatment of select CR infections are based mainly on small clinical trials and expert opinion [8].”
Li, D., Li, P., Yu, X., Zhang, X., Guo, Q., Xu, X., Wang, M., & Wang, M. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s305281 · Cited by 9
Wouters, C. L., Heydarian, N., Pusavat, J., Panlilio, H., Lam, A. K., Moen, E. L., Brennan, R. E., & Rice, C. V. (2023) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2023.184172 · Cited by 9
Chen, J., Lin, J., Weng, J., Ju, Y., & Li, Y. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09060-2 · Cited by 9
“Current clinical guidelines suggest using combination therapy to treat patients with severe CRPA infections [2, 3].”
BackgroundInfluentialWang, Y., Hu, H., Shi, Q., Zhang, P., Zhao, D., Jiang, Y., & Yu, Y. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2332658 · Cited by 8
Itoh, N., Akazawa, N., Yamaguchi, M., & Kawabata, T. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae678 · Cited by 8
“The prevalence of drug-resistant organisms varies significantly across different countries and regions, making it crucial to assess the effectiveness of ASPs in different settings [20].”
Morganella morganii: A Rare Cause of Early-Onset Neonatal Sepsis
Gameiro, I., Botelho, T., Martins, A. I., Henriques, R., & Lapa, P. (2023) · Cureus · doi:10.7759/cureus.45600 · Cited by 8
Fois, M., VITO, A. D., Cherchi, F., Ricci, E. D., Pontolillo, M., Falasca, K., Corti, N., Comelli, A., Bandera, A., Molteni, C., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13070616 · Cited by 8
“Current treatment guidelines from organizations such as the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) recommend broad-spectrum antibiotics, including CZA, for treating suspected or confirmed MDR Gram-negative infections [2,38].”
BackgroundWang, X., Meng, T., Dai, Y., Ou, H., Wang, M., Tang, B., Sun, J., Cheng, D., Pan, T., Tan, R., et al. (2024) · Infection · doi:10.1007/s15010-024-02365-z · Cited by 8
Kon, H., Lurie-Weinberger, M. N., Bechor, M., Temkin, E., Kastel, O., Schwartz, D. A., Keren‐Paz, A., Carmeli, Y., CRPA Working Group, Golan-Shany, O., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00965-24 · Cited by 8
Ali, S., Tobin, A., Lapthorne, S., Collison, M., Murphy, D., Chan, G., & Doyle, M. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001955 · Cited by 8
Khan, A., Manuel, C., Maynard, R., & Humphries, R. M. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01736-24 · Cited by 8
Chotiprasitsakul, D., Ao-udomsuk, K., & Santanirand, P. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.04.015 · Cited by 8
Rachina, S. A., Fedina, L. V., Витальевна, С. М., Sychev, I. N., Larin, E. S., & Alkhlavov, A. A. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.11.202467 · Cited by 9
Zhang, T., Wu, H., Ma, C., Yang, Y., Li, H., Yang, Z., Zhou, S., Shi, D., Chen, T., Yang, D., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.173221 · Cited by 8
Huang, C., Lin, L., & Kuo, S. (2024) · Antibiotics · doi:10.3390/antibiotics13090907 · Cited by 7
“The use of rifampin, imipenem/cilastatin, meropenem, or fosfomycin is not recommended as part of a combination treatment [52].”
BackgroundJin, D., Hu, D., & Jin, Y. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2025.2465129 · Cited by 7
“…of resistance, the recent 2023 Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections guidelines slightly favour the use of M-V above CAZ-AVI or Imipenem-cilastatin-relebactam for the treatment of KPC-pro-ducing CRE infections [38].”
Vlad, M. A., Dan, M., Catana, A. N., Dumitriu, S., & Tuchiluş, C. (2025) · Molecules · doi:10.3390/molecules30142950 · Cited by 7
“…Enterobacterales (CRE) represent a major public health concern, as these organisms either produce carbapenemases—enzymes belonging to the β -lactamase class that hydrolyze carbapenem antibiotics—or exhibit acquired resistance to carbapenems despite lacking intrinsic mechanisms [3,4].”
Requena‐Cabello, H., Rodríguez‐Guerrero, E., Ruíz, M. E., Navarro‐Marí, J. M., & Fernández, J. G. (2023) · Apmis · doi:10.1111/apm.13360 · Cited by 7
“…to the 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections of the Infectious Diseases Society of America (IDSA) [8], traditional non-carbapenem b - lactam agents (piperacillin-tazobactam, ceftazidime, cefepime, aztreonam) are preferred to treat P. aeruginosa…”
BackgroundStone, G. G., Wise, M. G. G., & UTT, E. A. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01473-23 · Cited by 7
A Difficult Case of Ventriculitis in a 40-Year-Old Woman with Acute Myeloid Leukemia
Rubino, R., Trizzino, M., Pipitò, L., Sucato, G., Santoro, M., Maugeri, R., Iacopino, D. G., Giammanco, A., Siragusa, S. M., & Cascio, A. (2024) · Antibiotics · doi:10.3390/antibiotics13050432 · Cited by 7
“Although we did not utilize intrathecal therapy in our patient, this should also be considered for patients with MDR CNS infection and for those who are refractory to systemic therapy [2,3,7].”
BackgroundMethodChen, Y., Fang, C., Luo, J., Pan, X., Gao, Z., Tang, S., & Li, M. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s463105 · Cited by 7
Ghareeb, A. M., Raafat, M. M., Bazan, N. S., & Samir, R. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00661-x · Cited by 7
Aslan, A. T., & Akova, M. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2408746 · Cited by 9
“‘Old-fashioned’ anti-biotics such as colistin, tigecycline, fosfomycin, and aminoglycosides have long been used to treat serious CRO infections [23,24].”
InfluentialWang, Y., Yu, L., Jianping, Z., Liang, G., Liu, J., Zheng, Y., Zhao, Y., & Yu, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-74290-y · Cited by 7
Jacobs, M. R., Good, C. E., Abdelhamed, A. M., Mack, A. R., Bethel, C. R., Marshall, S. H., Hujer, A. M., Hujer, K. M., Patel, R., van Duin, D., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01127-24 · Cited by 7
Self-citationLamba, B., Mir, M. A., Raja, V., Negi, N. P., Bhat, A. H., Ataya, F. S., Paul, N. D., & Batiha, G. E. (2024) · ChemistrySelect · doi:10.1002/slct.202304481 · Cited by 7
Rodríguez-Pallares, S., Mateo-Vargas, M. A., Rodríguez‐Iglesias, M., Arca-Suárez, J., & Galán‐Sánchez, F. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-05034-z · Cited by 7
Vuotto, F., Bru, J. P., Canouï, É., Caséris, M., Chopin, M., Cohen, R., Diamantis, S., Dinh, A., Fillâtre, P., Gauzit, R., et al. (2025) · Infectious Diseases Now · doi:10.1016/j.idnow.2025.105062 · Cited by 9
Lee, Y.-P., Liao, Y.-C., Chen, F.-J., Lin, T.-W., Huang, H.-P., Pan, H., & Liu, P. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.08.014 · Cited by 7
Cortegiani, A., Ingoglia, G., Ippolito, M., Girardis, M., Falcone, M., Pea, F., Pugliese, F. R., Stefani, S., Viale, P., & Giarratano, A. (2022) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-022-00062-7 · Cited by 7
“According to the Infectious Diseases Society of America (IDSA), cefiderocol is considered as one of the preferred options against NDM or other strains producing MBL and it is an alternative option in case of absence of certainty of carbapenemase resistance/presence of carbapenemase [38].”
MethodInfluence of Multiplex PCR in the Management of Antibiotic Treatment in Patients with Bacteremia
Andrei, A.-I., Tălăpan, D., Rafilă, A., & Popescu, G. A. (2023) · Antibiotics · doi:10.3390/antibiotics12061038 · Cited by 7
“Five Klebisella pneumoniae strains tested positive for NDM; in these cases, ceftazidime–avibactam was no longer efficient, and in the absence of cefiderocol, either colistin, tigecycline, or both can be used [30,31].”
Bloodstream Infections by AmpC-Producing Enterobacterales: Risk Factors and Therapeutic Outcome
Pospišil, M., Car, H., Gašparović, V. E., Beader, N., Herljević, Z., & Bedenić, B. (2023) · Pathogens · doi:10.3390/pathogens12091125 · Cited by 7
Wolfe, K. H., Pierce, V., & Humphries, R. M. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae075 · Cited by 7
Önal, U., Tüzemen, Ü., Kaya, P. K., İşçimen, R., Girgin, N. K., Özakın, C., Kahveci, F., & Akalın, H. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2349439 · Cited by 7
“…imipenem-cilastatin-relebactam and cefiderocol to address infections stemming from carbapenem-resistant Enterobacterales (CRE), the unavailability of agents like meropenem-vaborbactam, imipenem-cilastatin-relebactam and cefiderocol within our country poses a formidable challenge [4,5].”
Nohra, E. A., Appelbaum, R. D., Farrell, M. S., Carver, T. W., Jung, H. S., Kirsch, J. M., Kodadek, L. M., Mandell, S. P., Nassar, A. K., Pathak, A. S., et al. (2024) · Trauma Surgery & Acute Care Open · doi:10.1136/tsaco-2023-001303 · Cited by 8
Vyas, S., Patel, D., Bandali, A., Giordano, P., Roland, R., & Kessler, J. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116384 · Cited by 7
Woods, B. S., Schmitt, L. H. M., Janković, D., Kearns, B., Scope, A., Ren, S., Srivastava, T., Ku, C.-C., Hamilton, J., Rothery, C., et al. (2024) · Health Technology Assessment · doi:10.3310/ygwr4511 · Cited by 7
Kurt, A. F., Tanrıverdi, E. S., Yalçın, M., Bayramlar, O. F., Kaya, S. Y., Karaali, R., Kuşkucu, M. A., Çakırlar, F. K., Otlu, B., Balkan, İ. İ., et al. (2024) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2024.2024-5-99 · Cited by 7
“22 We employed blaVIM, blaIMP, blaOXA-48, blaNDM , and blaKPC primers to identify the resistance genes.”
Rodríguez-Pallares, S., Blanco-Martín, T., Lence, E., Aja‐Macaya, P., Sánchez-Peña, L., González-Pinto, L., Rodríguez–Mayo, M., Fernández-González, A., Galán‐Sánchez, F., Beceiro, A., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01307-24 · Cited by 7
Gatti, M., Rinaldi, M., Bonazzetti, C., Siniscalchi, A., Tonetti, T., Ambretti, S., Giannella, M., Viale, P., & Pea, F. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf098 · Cited by 7
Timbrook, T. T., & Fowler, M. J. (2023) · Antibiotics · doi:10.3390/antibiotics12091452 · Cited by 8
“Firstly, CRE is an extremely clinically challenging infection to manage, associated with significant morbidity and mortality [31].”
BackgroundJenrette, J. E., Coronato, K., Miller, M. A., Molina, K. C., Quinones, A., & Jacknin, G. (2024) · Academic Emergency Medicine · doi:10.1111/acem.14886 · Cited by 7
“10,11 Guidance is given to only use amikacin, gentamicin, or to-bramycin for complicated cystitis if therapeutic drug monitoring is available.”
Cefiderocol-associated brown chromaturia
Smith, M., & Foong, K. S. (2023) · BMJ Case Reports · doi:10.1136/bcr-2023-258207 · Cited by 6
“14 15 With the increasing prevalence of MDR infections, the utilisation of cefiderocol may experience a surge in demand.”
BackgroundTziolos, N., Karakonstantis, S., Kritsotakis, E. I., Vassilopoulou, L., Loukaki, M., Tovil, A., Kokkini, S., Tryfinopoulou, K., Ιωάννου, Π., Kondili, Ε., et al. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.07.016 · Cited by 6
Silva, A. S. D. N., da Silva, N. C. Z., do Valle, F. M., da Rocha, J., Ehrlich, S. R., & Martins, I. S. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s473789 · Cited by 6
Aslam, A., Jamshed, S. Q., Zin, C. S., Rahman, N. S. A., Ahmed, S. I., Szabó, Z. L., & Gajdács, M. (2024) · Antibiotics · doi:10.3390/antibiotics13111070 · Cited by 10
Brousse, X., Andry, F., Lahouati, M., Desmoulin, A., Lehours, P., Rignol, L., Petitgas, P., Leroy, A., & Charroyer, Q. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae449 · Cited by 6
Chotimakorn, P., Pattharachayakul, S., Lertsrisatit, Y., Santimaleeworagun, W., Tansakul, P., Yingkajorn, M., Chelae, S., Pomwised, R., Chukamnerd, A., Soontarach, R., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14030322 · Cited by 7
“…the clinical outcomes of infection, including age, gender, hospital ward, underlying diseases, source of infections, critically ill status, immunocompromised status, the duration of hospitalization, the use of invasive medical devices, antimicrobial therapy, and clinical laboratory test results.”
Chen, W., Chen, C.-L., Siu, L.-K. K., Chang, F., Yu, C.-M., Shang, H., Yang, Y., Lin, J., & Wang, C.-H. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf131 · Cited by 6
Antibiotics for Intra-Abdominal Infections: When, Which, How and How Long?
Sartelli, M., Palmieri, M., & Labricciosa, F. M. (2025) · Antibiotics · doi:10.3390/antibiotics14111127 · Cited by 8
“European Society of Clinical Microbiology and Infectious Diseases Society of America lists eravacycline as an alternative for ESBL-and CPE-related infections (including KPC, MBL, OXA-48), except for primary BSIs and urinary tract infections [82].”
Wong, C. P., Delate, T., Hudson, E., Nguyen, J. K., Yang, S.-J., & Abraham, M. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06458-0 · Cited by 6
“They did not comprise the backbone of the ASI because of association of higher rates of clinical failure or lower level of evidence supporting use [24].”
Background
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.